BACKGROUND: Cytokines are and may be used as therapeutic targets in cancer therapy. In breast cancer, interleukin (IL)-6 is associated with different features of tumor biology like metastasis, certain stages, and decreased survival. It is now an established fact that signaling via the soluble IL-6 receptor (sIL-6R) («transsignaling») is an important process in the IL-6 machinery. METHODS AND RESULTS: In this mini-review, we discover that published knowledge about sIL-6R serum levels in breast cancer patients is sparse and, furthermore, most in vitro data merely show that tumor cells produce the sIL-6R endogenously. CONCLUSIONS: Therefore, a lot of research is still necessary to analyze the significance of the sIL-6R and therefore the transsignaling process in breast tumors. More knowledge about the sIL-6R in breast cancer would give insights into its putative role as blood marker of active tumor disease. Secondly, the sIL-6R may be useful in breast cancer as a new therapeutic pathway. If, as suggested by the literature, IL-6 mediates the aggressiveness and the growth of breast tumors, elevated circulating levels of IL-6 and its receptor may identify patients for whom the IL-6 complex is a therapeutic target.
BACKGROUND: Cytokines are and may be used as therapeutic targets in cancer therapy. In breast cancer, interleukin (IL)-6 is associated with different features of tumor biology like metastasis, certain stages, and decreased survival. It is now an established fact that signaling via the soluble IL-6 receptor (sIL-6R) («transsignaling») is an important process in the IL-6 machinery. METHODS AND RESULTS: In this mini-review, we discover that published knowledge about sIL-6R serum levels in breast cancerpatients is sparse and, furthermore, most in vitro data merely show that tumor cells produce the sIL-6R endogenously. CONCLUSIONS: Therefore, a lot of research is still necessary to analyze the significance of the sIL-6R and therefore the transsignaling process in breast tumors. More knowledge about the sIL-6R in breast cancer would give insights into its putative role as blood marker of active tumor disease. Secondly, the sIL-6R may be useful in breast cancer as a new therapeutic pathway. If, as suggested by the literature, IL-6 mediates the aggressiveness and the growth of breast tumors, elevated circulating levels of IL-6 and its receptor may identify patients for whom the IL-6 complex is a therapeutic target.
Entities:
Keywords:
Breast cancer; IL-6; Transsignaling; sIL-6R
Authors: E Jabłońska; M Kiluk; W Markiewicz; L Piotrowski; Z Grabowska; J Jabłoński Journal: Arch Immunol Ther Exp (Warsz) Date: 2001 Impact factor: 4.291
Authors: M Peters; S Jacobs; M Ehlers; P Vollmer; J Müllberg; E Wolf; G Brem; K H Meyer zum Büschenfelde; S Rose-John Journal: J Exp Med Date: 1996-04-01 Impact factor: 14.307
Authors: Stephanie C Casey; Amedeo Amedei; Katia Aquilano; Asfar S Azmi; Fabian Benencia; Dipita Bhakta; Alan E Bilsland; Chandra S Boosani; Sophie Chen; Maria Rosa Ciriolo; Sarah Crawford; Hiromasa Fujii; Alexandros G Georgakilas; Gunjan Guha; Dorota Halicka; William G Helferich; Petr Heneberg; Kanya Honoki; W Nicol Keith; Sid P Kerkar; Sulma I Mohammed; Elena Niccolai; Somaira Nowsheen; H P Vasantha Rupasinghe; Abbas Samadi; Neetu Singh; Wamidh H Talib; Vasundara Venkateswaran; Richard L Whelan; Xujuan Yang; Dean W Felsher Journal: Semin Cancer Biol Date: 2015-04-10 Impact factor: 15.707
Authors: Smruthi Vijayaraghavan; Merih Guray Durak; Nicole M Kettner; Tuyen Bui; Mehrnoosh Kohansal; Min Jin Ha; Bin Liu; Xiayu Rao; Jing Wang; Min Yi; Jason P W Carey; Xian Chen; T Kris Eckols; Akshara S Raghavendra; Nuhad K Ibrahim; Meghan Sri Karuturi; Stephanie S Watowich; Aysegul Sahin; David J Tweardy; Kelly K Hunt; Debu Tripathy; Khandan Keyomarsi Journal: Clin Cancer Res Date: 2019-03-13 Impact factor: 12.531